

## Technology Advisory Interests Register

Topic: Lenacapavir for preventing HIV-1 in people 16 years and over [ID6495]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	TAC Committee Member	Financial	In the past 12 months I have worked with Gilead, a listed comparator company, in unrelated indications of MASH and Gastric Cancer.	05/02/2026	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal.
Jon Tosh	TAC Committee Member	Non-financial professional	I work for ViiV Healthcare, who are a comparator company.	09/02/2026	It was agreed that Jon's declaration would prevent them from participating in discussions on this appraisal.
Dr Iain Reeves	Expert	Direct - financial	<ul style="list-style-type: none"> <li>In the last year I have received an honorarium for participation in an advisory board for Gilead Sciences.</li> <li>I have also received speaker fees and honoraria from ViiV Healthcare and MSD.</li> <li>I am a paid consultant undertaking occasional work as a speaker in events organised by ViiV Healthcare, who could be</li> </ul>	30/09/2025	It was agreed that Dr Reeves's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>regarded as the main competitor to Gilead in this area.</p> <ul style="list-style-type: none"> <li>I have no current or future arrangements for paid work with Gilead.</li> </ul>		
		Direct – non-financial	I am a principal investigator on the PURPOSE 5 study, which is sponsored by Gilead.		
Dr Rachael Jones	Expert	Non-financial professional	The company have sponsored trials in my trust.	03/03/2026	It was agreed that Dr Jones’s declaration would not prevent them from providing expert advice to the committee
Dr Hamish Mohammed	Expert	Direct - financial	I receive honoraria to review research grants for the European Science Foundation, and for an annual lecture at the London School of Hygiene and Tropical Medicine.	26/02/2026	It was agreed that Dr Mohammed’s declaration would not prevent them from providing expert advice to the committee
		Direct – non-financial	<ul style="list-style-type: none"> <li>Member of the British Association for Sexual Health and HIV (current)</li> <li>Past member of the Medical Board of Naz, a sexual health charity (this was an unpaid position; this board has not</li> </ul>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>been active in the last 12 months)</p> <ul style="list-style-type: none"> <li>• Author of scientific articles with estimates of HIV incidence</li> </ul>		
		Indirect	<p>(Hamish works for UK Health Security Agency (UKHSA) who have the following interests:</p> <ul style="list-style-type: none"> <li>• Gilead has funded UKHSA to perform the <a href="#">Positive Voices survey of people living with HIV</a>; they've also funded someone in another division at UKHSA to do a presentation on anti-fungals</li> <li>• Advanz has funded UKHSA for a project evaluating antibiotics).</li> </ul>		
Juddy Otti	Expert	Direct - financial	I have received honorarium for presenting at conferences and sitting on advisory boards however this didn't include Lenacapavir	23/07/2025	It was agreed that Juddy's declaration would not prevent them from providing expert advice to the committee
Dr Leonardo De Oliveira	Expert	Direct – non-financial	I am Head of Development and Outreach at The Love Tank, a non-profit organisation that advocates for equitable access to HIV prevention tools. While The Love Tank does not accept pharmaceutical funding, we	23/07/2025	It was agreed that Dr De Oliveira's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>have taken public positions in support of expanding PrEP options, including long-acting injectable forms. My organisation has contributed to community-facing research and advocacy reports related to PrEP access and barriers. These contributions may be seen as relevant non-financial interests in terms of professional advocacy. (Start: ongoing; no specific end date)</p>		

DRAFT